Compare Citius Pharmaceuticals Inc (CTXR) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Northrop Grumman Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Northrop Grumman Corporation trades at $483 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 5053.6× Citius Pharmaceuticals Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Northrop Grumman Corporation for 81 Days on average.
| CTXR | NOC | |
|---|---|---|
Market Cap | $13.62M | $68.83B |
Volume | 132,438 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $1.82 | $768.02 |
52-Week Low | $0.48 | $473.46 |
Typical Hold Time | 16 Days | 81 Days |
Enterprise Value | $3.79M | $82.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Northrop Grumman (NOC) trades at $473.46, down 2.0% on the day, reflecting a bearish technical signal amid recent contract loss news. The stock exhibits strong fundamentals with a P/E of 15.05, net income margin of 10.48%, and consistent earnings beats in recent quarters. Revenue growth is steady, supported by a record backlog, though the loss of the $20 billion Navy F/A-XX contract to Boeing introduces competitive pressure.
The outlook remains supported by robust defense budgets and key programs like the B-21 bomber, but investor sentiment is cautious near-term. Analyst consensus is bullish with a $600.62 price target, though technical indicators suggest potential near-term weakness. Risks include contract dependencies and macroeconomic shifts in defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
